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Abstract
Background: We depicted gender-differences in metabolic 
syndrome (MS) clustering before and after puberty in 
pediatrics, in order to develop gender specific preventive 
strategies for childhood obesity.
Methods: We considered 1079 children and adolescents 
(529 females and 550  males; mean age 11.5 ± 2.8 year). 
According to body mass index (BMI) percentiles the sub-
jects were classified as normal weight BMI <75th, over-
weight BMI 75–95th and with obesity BMI >95th. MS was 
diagnosed when three of the following criteria for age 
and sex percentiles were met: BMI >95th, triglycerides 
(TGs) level >95th, high-density lipoprotein-cholesterol 
(HDL-c) level <5th, blood pressure (blood pressure) >95th 
percentile, fasting blood glucose (FBG) >100  mg/dL 
and/or homeostatic model assessment- insulin resistance 
(HOMA-IR) >97.5th percentile.
Results: The prevalence of dismetabolic factors was 
similar in both genders, except for pathological BP, 
which was higher in males (p = 0.02). MS was detected 
only in patients with obesity, with a higher prevalence 
in pubertal than late/post-pubertal subjects (p < 0.001), 
without any significant difference between gender. In pre-
puberty, the most common MS combination was obesity 
(HBMI) + hypertension (HBP) + hyperglycemia/insulin 
resistance (HGLY/IR) followed by HBMI + low HDL-levels 
(LHDL) + HGLY/IR versus HBMI + HBP + HGLY/IR fol-
lowed by HBMI + HBP + LHDL, respectively, in females 
and males. In the early and late/post- pubertal periods, 
the most prevalent combination remained similar to 
pre-puberty, additionally in both sexes other combina-
tions, such as HBMI + HTG + HBP + HGLY/IR, HBMI +  
HBP + LHDL + HGLY/IR, HBMI + HTG + LHDL + HGLY/IR 
and HBMI + HTG + LHDL + HBP + HGLY/IR were also 
detected, differently distributed in males and females.
Conclusions: We confirm that MS is an important conse-
quence related to obesity, particularly in the post-puberty 
stage. Some gender-based differences should be con-
sidered early in order to identify specific preventive and 
treatment strategies.
Keywords: adolescents; children; combination; gender; 
metabolic syndrome; sex.
Introduction
Metabolic syndrome (MS) is defined as a cluster of several 
metabolic factors including obesity, abnormalities in 
glucose metabolism, hypertension and dyslipidemia, 
which increase the risk of diabetes mellitus and cardio-
vascular disease [1, 2]. The development of metabolic 
complication in the pediatric age is directly linked to both 
excessive weight gain and early onset of obesity [3–6].
There are key aspects of metabolic homeostasis that 
are regulated differently in males and females [7] and it 
has been reported that the prevalence of different combi-
nations of MS factors are otherwise expressed by gender 
[8, 9].
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The major contributors of gender dimorphisms 
in glucose, lipid and energy homeostasis are “activa-
tion” effects of estrogens and androgens acting on their 
 receptors after the onset of puberty. There are several 
studies demonstrating differences in the incidence of 
 cardio-metabolic risk factors in obese children according 
to their gender, as well as pubertal status [10–17], however, 
the combinations and interactions of the clustered MS risk 
factors, are not fully detailed in the pediatric age.
The aim of this cross-sectional study was to describe 
the gender differences in MS clustering before and after 
puberty in children and adolescents, in order to identify 
early childhood prevention intervention and treatments 
for at high risk children.
Subjects and methods
Subjects
From October 2016 to October 2018, 1079 Caucasian children and ado-
lescents (529 females and 550 males) aged 2–18 years, referred to our 
outpatients’ clinic for auxological evaluation (growth assessment, 
rapid weight changes) or for obesity by their general practitioner or 
primary care pediatrician, were consecutively included in the study.
According to the Italian Society for Pediatric Endocrinology 
and Diabetology (ISPED) criteria [18], the subjects were classified as 
normal weight, body mass index (BMI) <75th percentile; overweight, 
BMI 75–95th percentile; with obesity, BMI >95th percentile [19]. This 
classification was preferred since the ISPED and International Obe-
sity Task Force (IOTF) systems of overweight and obesity assessment 
are similar and more specific in identifying obese children/adoles-
cents with clustered cardiometabolic risk factors compared to the 
World Health Organization (WHO) criteria [18].
Exclusion criteria were: use of any medication, concomitant 
chronic or acute illnesses, known secondary obesity condition.
The study protocol was approved by the Ethical Committee of 
Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. The study 
was conducted in accordance with the 1975 Helsinki Declaration, as 
revised in 2008. All participants, or their responsible guardians, were 
asked to sign a written consent after being informed about the nature 
of the study.
Physical examination
Physical examination of the participants included evaluation of 
height, weight, waist circumference (WC), BMI (calculated as body 
weight in kilograms divided by height in meters squared), pubertal 
stage according to Marshall and Tanner (stage characteristics corre-
sponding to Tanner stage 1) [20, 21], and blood pressure (BP) meas-
urement. Waist to height ratio (WHtR) was also calculated to estimate 
adiposity distribution.
Anthropometric measurements were performed as previously 
reported [22]. Blood pressure (BP) was measured using a mercury 
sphygmomanometer, after the participant sat comfortably for 5 min, 
with an appropriately sized cuff on the right arm, which was slightly 
flexed at heart level, for two consecutive times. The second BP meas-
urement was used for analysis [22].
Pubertal maturation was assessed using the pubertal staging 1–5, 
for breast development, pubic hair and genitalia determined by visual 
inspection as described by Marshall and Tanner (Tanner staging). Clin-
ical examination was performed by an experienced endocrinologist 
pediatrician (VC) to guarantee the quality assurance. Pubertal devel-
opment was classified as: prepubertal: boys with genital Tanner stage 
1, girls with breast Tanner stage I; early pubertal: boys with genital 
Tanner stage 2–3; girls with breast Tanner stage 2–3; late/post pubertal: 
boys with genital Tanner stage ≥4; girls with breast Tanner stage ≥4).
Elevated systolic blood pressure (SBP) or diastolic blood pres-
sure (DBP) was defined when values exceeded the 95th percentile for 
age and sex [23].
Biochemical parameters and definitions
Blood samples were drawn in the morning, after an overnight fast. 
Metabolic blood assays included fasting blood glucose (FBG), total 
cholesterol (TC), high-density lipoprotein-cholesterol (HDL-c), tri-
glycerides (TGs), insulin, aspartase aminotransferase (AST), alanine 
aminotransferase (ALT) and gamma glutamyl transpeptidase (GGT).
Plasma glucose was measured using the hexokinase-G-6-phos-
phate dehydrogenase method (Siemens Healthcare Diagnostics, 
Camberley, UK) with a chemistry analyzer (Advia XPT, Siemens, 
Camberley, UK). The TC was determined by an enzymatic method 
(Advia XPT, Siemens Healthcare Diagnostics, Camberley, UK). HDL-c 
was measured by the selective detergent method followed by enzy-
matic reactions (Siemens Healthcare Diagnostics, Camberley, UK). 
TG concentration was measured by the glycerol phosphatase oxidase 
method (Siemens Healthcare Diagnostics, Camberley, UK). Serum 
insulin was determined by a solid-phase, two-site chemiluminescent 
immunometric assay with an immunochemistry analyzer (Immulite 
2000, Siemens Healthcare Diagnostics, Camberley, UK). AST, ALT 
and GGT were measured with a chemistry analyzer (Advia XPT, Sie-
mens Healthcare, Camberley, UK) equipped with dedicated reagents; 
the method for the transaminase assay is based on nicotinamide ade-
nine dinucleotide phosphate (NADH) monitoring by ultraviolet (UV) 
detection without addition of P-5′-P. The method for the GGT assay is 
based on the transfer of the gamma-glutamyl group from L-gamma-
glutamyl-3-carboxy-4-nitroaniline to the glycilglycine acceptor, to 
yield 3-carboxy-4-nitroaniline [22].
Elevated FBG was defined when values exceeded 100 mg/dL and 
impaired insulin sensitivity (ISI). Insulin resistance was determined 
by the homeostasis model assessment for insulin resistance (HOMA-
IR) using the formula: insulin resistance = (insulin × glucose)/22.5. 
Impaired insulin sensitivity was defined with HOMA-IR whenever 
exceeding the 97.5th percentile for age and sex and for Italian chil-
dren and adolescents [24].
Triglyceride-glucose index (TyG index) was evaluated using the 
formula (ln[fasting triglycerides (mg/dL) × fasting plasma glucose 
(mg/dL)/2]), as a surrogate marker of IR and predictor of diabetes, 
TyG index was considered pathological with a cutoff exceeding 7.88, 
according to Vieira Ribeiro [25].
Abnormal hepatic function was defined with pathological 
increase of ALT and AST and/or GGT.
As previously reported [5, 6], we diagnosed MS according 
to the modified criteria from the National Cholesterol Education 
Program’s Adult Treatment Panel III (NCEP-ATPIII), the WHO and 
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the International Diabetes Federation. Patients were classified as 
 having MS if they met three of the following criteria for age and 
sex: BMI >95th percentile, TG level >95th percentile, HDL-c level 
<5th percentile, SBP and/or DBP >95th percentile, FBG >100  mg/
dL and/or HOMA-IR >97.5th percentile. As previously described [5], 
we used BMI as a criterion for MS as it correlates with visceral fat, 
blood pressure and dyslipidemia; furthermore, BMI percentiles for 
the Italian population are available [19]. Although WC in children is 
a good predictor of visceral adiposity, it might not detect differences 
in body proportions related to puberty. WC percentile nomograms 
in children have only recently become available for some ethnic 
groups but are not available for all and there is no internationally 
accepted classification of age-specific cut-off values [26, 27]. Patho-
logical level of FBG and/or alteration of ISI were selected as markers 
of glucometabolic derangement, as impaired glucose tolerance and/
or diabetes is rare in childhood and IR precedes glucose abnormali-
ties playing an important role in the pathogenesis of normal glucose 
tolerance to impaired glucose tolerance transition [28]. The euglyce-
mic-hyperinsulinemic clamp is the gold standard for measuring IR, 
but this study is invasive, time consuming and difficult to apply to 
children in a clinical setting. For these reasons, we used HOMA-IR as 
a surrogate marker of IR/sensitivity [29]. Finally, blood pressure and 
fasting lipid levels were compared with population norms adjusted 
for age and sex.
Statistical analysis
Power consideration: considering about 50% of patients are males 
and about one third are prepuberal, about 1070 patients allows more 
than 80% power to find significant (p < 0.05) differences between 
groups in proportion of MS and its components of about 5–10%.
Qualitative variables were described as counts and percentage. 
The Shapiro-Wilk test was used to test the normal distribution of quan-
titative variables. As quantitative variables were normally distributed, 
the results were expressed as the mean value and standard deviation 
(SD). To study the association between clinical and metabolic data as 
independent variables and sex and pubertal stage (as explanatory 
variables) univariate linear regression models were fitted considering 
also an interaction term between gender and pubertal stage.
To study the association between pathological auxological and 
metabolic parameters and gender and pubertal stage (as explanatory 
variables) univariate binary logistic regression models were fitted 
considering also an interaction term between gender and pubertal 
stage.
All tests were two-sided and a p-value below 0.05 was consid-
ered statistically significant. The data analysis was performed with 
the STATA statistical package (release 15.1, 2017, Stata Corporation, 
College Station, TX, USA).
Results
Clinical and metabolic data
No statistical differences were found between males and 
females for age and pubertal stage.
In Tables 1 and 2, clinical and metabolic data of the 
enrolled subjects and regression analysis of the para-
meters are reported.
Compared to females, males showed higher WC 
(p = 0.003), glucose levels, (<0.001), SBP (p < 0.01), triglyc-
eride glucose (TyG) index (p = 0.04) and WHtR (p = 0.007), 
Table 2.
Compared to prepubertal subjects, early pubertal 
patients showed significant differences in all parameters 
included in the evaluation except for BMI-standard devia-
tion score (SDS), WHtR, HDL-c and TC, ALT and GGT and 
late/post-pubertal patients in all parameters except for 
HDL-c and TC, DBP, ALT and GGT, Table 2.
BMI-SDS (p < 0.001), insulin and HOMA-IR (p < 0.001), 
WHtR (p < 0.01), BP (p < 0.001) were higher in late/post-
pubertal than in early pubertal patients.
The difference between genders is evident both before 
and during puberty for TyG (p = 0.04) and WHtR (p = 0.04) 
in early puberty and for insulin (p = 0.01), HOMA-IR 
(p < 0.01), HDL-c (p = 0.01), WHtR (p = 0.02) and ALT 
(p = 0.04) in late/post-puberty, Table 2.
Clustering of dismetabolic factors
Based on the BMI percentiles threshold, 190 out of 1079 
patients (17.6%) were normal weight, 271 (25.11%) over-
weight and 618 (57.27%) affected by obesity. The distribu-
tion was not significantly different between gender and 
pubertal stages.
The percentage of patients with pathological auxo-
logical and metabolic parameters and the logistic analysis 
are reported in Tables 3–4.
The prevalence of dismetabolic factors was similar 
in males and females except for pathological BP that was 
higher in males (p = 0.01).
Compared to pre-pubertal children, early puber-
tal subjects showed a higher prevalence of pathological 
HOMA-IR (p = 0.001), TyG index (p = 0.005) and WHtR 
(p = 0.01) and late/post pubertal patients revealed a 
higher prevalence of pathological HOMA-IR (p < 0.001), 
HDL-c (p = 0.05), BP (p = 0.01) and TyG index (p = 0.008) 
without difference between gender, Table 4.
The prevalence of pathological parameters is not 
 different in early and late/post-pubertal subjects, except 
for HOMA-IR (p = 0.01).
MS was detected only in patients with obesity 
(14.27%). The prevalence of MS was similar in prepuber-
tal and early pubertal subjects (10.3% vs. 11.8%, p = 0.1) 
and higher in late/post-pubertal (27.6% vs. 10.3 p < 0.001 
and 27.6% vs. 11.8%, p < 0.01), without any significant 
 difference between males and females.
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Combination of MS components
As reported in Figure 1 and Table 5, dismetabolic factors 
presented alone or associated with one to four other para-
meters, with different combinations according to gender 
and puberty.
In pre-puberty, the most common combination was 
obesity (HBMI) + hypertension (HBP) + hyperglycemia/
insulin resistance (HGLY/IR) followed by HBMI + low HDL-
levels (LHDL) + HGLY/IR in females and HBMI + HBP + HGLY/
IR followed by HBMI + HBP + LHDL in males (Table 5).
As reported in Table 5, in the early and late/post-
pubertal period, the most prevalent combination remained 
similar to pre-puberty, additionally in both sexes other 
combinations, such as HBMI + HTG + HBP + HGLY/IR, 
HBMI + HBP + LHDL + HGLY/IR, HBMI + HTG + LHDL + HGLY/
Table 3: Prevalence of the pathological parameters in the enrolled patients according to gender and pubertal stage.
Parameters  
 
Females  
 
Males
Prepubertal   Early pubertal   Late pubertal Prepubertal   Early pubertal   Late pubertal
BMI >95° centile   50.58%   53.21%   78.26%   60.51%   53.55%   64.86%
FBG >100 mg/dL   1.74%   1.51%   5.43%   1.27%   1.06%   1.80%
HOMA-IR >97° centile   20.93%   20.93%   31.32%   14.65%   15.29%   24.82%
HDL-c < 5° centile   9.88%   14.34%   18.48%   11.46%   12.77%   26.13%
TC >95° centile   11.63%   7.17%   13.04%   13.38%   10.28%   9.01%
TGs >95° centile   5.23%   4.15%   5.32%   2.55%   10.87%   8.11%
BP >95° centile   9.88%   13.96%   20.65%   19.75%   17.73%   25.23%
TG index >7.88   37.21%   50.94%   54.35%   51.82%   49.65%   63.06%
WHtR >0.5   41.86%   54.34%   47.83%   41.40%   56.03%   54.05%
Pathological liver enzymes   5.23%   4.53%   8.70%   3.18%   3.90%   9.01%
Abbreviations as for Table 1.
Table 4: Pathological parameters according to gender and pubertal stage: logistic regression.
Parameters  
 
p-Value OR (95%CI)
Females vs. 
males
  Pre-pubertal vs. 
early pubertal
  Pre-pubertal vs. 
late pubertal
  Gender and early 
puberty interaction
  Gender and late 
puberty interaction
BMI >95° centile   0.75   0.43   0.21   0.29   0.68
  1.09 (0.62–1.91)   1.23 (0.74–2.02)   1.58 (0.77–3.24)   0.68 (0.34–1.39)   0.81 (0.31–2.17)
FBG > 100 mg/dL   0.73   0.84   0.11   0.29   0.1
  0.72 (0.11–4.40)   0.86 (0.19–3.90)   3.23 (0.75–313.86)   0.97 (0.09–10.11)   0.43 (0.03–5.10)
HOMA-IR >97° centile   0.14   0.01   <0.001   0.86   0.95
  0.64 (0.36–1.15)   1.72 (0.01–1.09)   3.17 (1.82–5.50)   1.06 (0.53–2.09)   1.02 (0.45–2.27)
HDL-c <5° centile   0.64   0.17   0.05   0.47   0.59
  1.10 (0.58–2.38)   1.52 (0.83–2.80)   2.06 (0.99–4.27)   0.72 (0.31–1.71)   1.30 (0.49–3.44)
TC >95° centile   0.63   0.11   0.73   0.60   0.30
  1.17 (0.60–2.25)   0.58 (0.30–1.13)   1.14 (0.53–2.45)   1.26 (0.51–3.08)   0.56 (0.18–1.69)
TGs >95° centile   0.22   0.59   0.09   0.17   0.58
  0.47 (0.14–1.56)   0.78 (0.31–1.93)   2.20 (0.86–5.64)   2.73 (0.64–11.55)   1.52 (0.33–7.03)
BP >95° centile   0.01   0.20   0.01   0.18   0.23
  2.24 (1.18–4.23)   1.47 (0.80–2.72)   2.37 (1.16–4.38)   0.58 (0.26–1.29)   0.57 (0.22–1.43)
TG index >7.88   0.08   0.005   0.008   0.12   0.95
  1.46 (0.94–2.27)   1.75 (1.18–2.59)   2.00 (1.20–3.35)   0.64 (0.37–1.99)   0.97 (0.47–1.99)
WHtR >0.5   0.93   0.01   0.35   0.31   0.74
  0.98 (0.63–1.52)   1.65 (1.12–2.43)   1.27 (0.76–2.11)   1.09 (0.62–1.89)   1.30 (0.64–2.65)
Pathological liver enzymes   0.36   0.73   0.28   0.61   0.46
  0.59 (0.19–1.81)   0.85 (0.35–2.08)   1.72 (0.64–4.63)   1.43 (0.35–5.78)   1.74 (0.39–7.66)
Abbreviations as for Table 1.
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IR and HBMI + HTG + LHDL + HBP + HGLY/IR were also 
detected, differently distributed in males and females.
Discussion
The present study focused on the prevalence and char-
acteristics of MS in a pediatric population according 
to gender and pubertal status. We confirmed a higher 
prevalence of MS in children with obesity compared 
to normal weight ones as well as in late/post-pubertal 
than in pre-pubertal subjects, without any significant 
gender difference. Though the most common combi-
nation of MS components does not differ by gender, 
some sex-based differences and an increased number 
of MS components at early and late/post-puberty were 
detected.
Table 5: Combination of metabolic syndrome components according to pubertal stage and gender.
Combinations  
 
Prepubertal  
 
Early pubertal  
 
Late pubertal
Females   Males Females   Males Females   Males
Three components
 HBMI + HTG + HGLY/IR   6.67%   0%   5.56%   0%   8%   0%
 HBMI + HTG + HBP   6.67%   0%   2.78%   0%   0%   3.03%
 HBMI + HTG + LHDL   1.33%   5.56%   2.78%   0%   0%   3.03%
 HBMI + LHDL + HBP   0%   33.3%   0%   6.9%   8%   12.12%
 HBMI + LHDL + HGLY/IR   26.67%   16.67%   36.11%   20.69%   20%   24.24%
 HBMI + HBP + HGLY/IR   40%   38.89%   30.56%   17.24%   28%   24.24%
Four components
 HBMI + HTG + LHDL + HGLY/IR   0%   0%   2.78%   10.34%   12%   6.06%
 HBMI + HTG + HBP + HGLY/IR   0%   0%   2.78%   6.9%   4%   3.03%
 HBMI + LHDL + HBP + HGLY/IR   6.67%   5.56%   13.89%   27.59%   12%   18.18%
Five components
 HBMI + HTG + LHDL + HBP + HGLY/IR  0%   0%   2.78%   10.34%   4%   6.06%
HBMI, obesity (BMI >95° centile); HTG, hypertriglyceridemia (TG >95° centile); LHDL-c, low levels of high density lipoprotein cholesterol 
(HDL-c <5th centile); HBP, hypertension (Blood pressure >95th centile); HGLY/IR, hyperglycemia (FBG >100 mg/dL) and/or insulin resistance 
(HOMA-IR > 97th centile).
Figure 1: Distribution of combination of 1–5 pathological metabolic syndrome components according to pubertal stage and gender.
(BMI, body mass index; Glyc, glycemia; HOMA-IR, homeostasis model assessment for insulin resistance; HDL-Chol, HDL-cholesterol; BP, 
blood pressure).
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MS is defined by a constellation of physiological, 
biochemical, clinical and metabolic factors that directly 
increase the risk of atherosclerosis, type 2 diabetes 
 mellitus (T2DM), and all-cause mortality [1–6].
In the pediatric age, it is difficult to estimate MS prev-
alence as many different criteria have been used in multi-
ple definitions. The literature reports prevalence ranging 
from 0.2% to 38.9%, with a median prevalence of 11.9% 
(range 2.8–29.3%) and 29.2% (range 10–66%), respec-
tively, in overweight children and in those with obesity; 
for non-obese, non-overweight populations, the range 
was 0–1% [2].
We noted a higher prevalence of MS in prepubertal 
than late/post-pubertal children with obesity. Although 
the pathogenesis of MS is not completely understood, 
recent data suggest that interaction between obesity, IR 
and inflammation play a key-role in the development [15]. 
Notably, puberty is associated with a progressive marked 
decrease in insulin sensitivity and this normal tendency 
for IR during puberty may be considered a natural cofac-
tor for the development of MS [30].
As far as gender distribution, published reports 
showed interesting differences in adults [31, 32]. Results 
are mixed showing, on the one hand, a higher MS inci-
dence in males [31, 32] and on the other hand, a higher 
MS incidence in females [33, 34]. These conflicting results 
are probably due to an intrinsic sexual dimorphism in MS 
susceptibility, which probably relates to various factors, 
including the influence of androgens and estrogens on a 
multitude of metabolic and vascular biological processes 
[35]. Besides, although androgens and estrogens are the 
main sex hormones, respectively, for males and females, 
we should not forget that they are present in both genders, 
albeit in different concentrations, exerting different 
effects. Additionally, gender differences on gene expres-
sion (especially genes located on the X chromosome) may 
predispose to different cardio-metabolic risks [35]. Yet 
environmental factors and lifestyle behaviors have been 
shown to be implicated.
In children and adolescents, only a limited number 
of studies reports gender differences on metabolic risk 
factors for MS [10–13]. Our results confirm data previ-
ously published, showing no significant gender differ-
ences in MS prevalence [11, 12], however, the prevalence 
of some MS components, such as high SBP, was higher in 
males than in females. In our population, children with 
obesity did not exhibit a higher impaired fasting glucose 
in males nor a higher predominance of IR in females [36]. 
Despite sex hormone levels, androgen/estrogen balance 
may play an important role in the development of MS; 
also in children and adolescents [37, 38], the different 
impact of gender on MS in the pediatric age, supports 
the hypothesis that polygenic contribution is probably of 
utmost importance, along with hormonal factors. Collec-
tion of data on genomics, metabolomics, gut microbiota 
besides deep phenotyping and environmental variables, 
including diet and lifestyle, may better explain inter- and 
intra-individual differences, upgrading a stratified level 
of diagnosis and intervention by means of conventional 
guidelines for population subgroups to a precision indi-
vidual approach level of diagnosis and tailored preven-
tion/treatment interventions.
As reported in adults [39], different combination pat-
terns of MS components are detected according to gender, 
moreover the most frequent combination pattern of MS is 
obesity + hypertension + hyperglycemia/IR both in females 
and males. These data confirm that IR and compensa-
tory hyperinsulinemia is frequent in the pediatric age and 
support the hypothesis that IR could be a key factor linking 
obesity to the onset of the metabolic comorbidities also in 
the pediatric age. Additionally, the results identify hyper-
tension as a common manifestation of the metabolic dis-
turbances associated with IR and hyperinsulinemia. The 
causative role of insulin in hypertension development is 
still questioned [5, 6]; hypertension could be secondary 
to a combination of IR, autonomic dysfunction, abnormal 
vascular structure and function related to a dysregulated 
production of specific adipokines in subjects with obesity.
At puberty, in our population a rising number of MS 
components was observed, with different percentages at 
early and late/post-pubertal stage, supporting a higher 
risk for persistence throughout adult life and confirm-
ing that a prompt identification and treatment of meta-
bolic complications in pediatric obesity is recommended 
both for the present and future health of the child [5, 6]. 
However, the authors acknowledge some limitations of 
the study, including the possible confounders for MS 
development such as physical activity, dietary habits 
and socioeconomic status, that should be considered in 
future research for a deeper and more comprehensive 
understanding. Secondly, it should be clear that this 
cross-sectional study may not provide definite informa-
tion but can offer a hook for future investigations with 
longitudinal studies that are more likely to suggest cause 
and effect as for MS medical complications development. 
The study was performed on a clinical population and not 
on a general one. This is a study limitation as far as preva-
lence is concerned, as we acknowledge that it is not repre-
sentative for the whole pediatric population. On the other 
hand, it is necessary to recognize the difficulty to recruit 
subjects from the general population for studies with 
invasive measurements such as blood draw, that, among 
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other things, are expensive and not supported by the 
health care system. Finally, the concept of cardiovascular 
risk factors stability during puberty progression remains 
unsolved. Reinehr et al. [14, 16] described that changing 
from mid- to late-puberty is associated with improvement 
of these factors; on the other hand, it has been reported 
that metabolic alterations do not revert to prepubertal 
values [40, 41]. We noted some differences in the distri-
bution of the dismetabolic parameters between early and 
late/post-puberty, moreover in our pediatric population 
it is not possible to define the evolution of these factors. 
However, our study provides an analysis of a considerable 
sample size useful to provide important information for 
future longitudinal cohort studies. In addition it delivers 
evidence on occurrence and exposure, useful for assess-
ment and interventions tailored for children with obesity 
at high risk of metabolic and cardiovascular disease.
Our results indeed confirm that MS is an important 
consequence related to obesity, particularly in the post-
puberty period. No significant difference in the prevalence 
of MS was noted between females and males, however, 
some gender-based differences observed in our sample 
should be investigated more and considered in order to 
develop gender specific preventive strategies, particularly 
when puberty begins.
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